Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00055757 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: tipifarnib
DRUG: cisplatin
DRUG: gemcitabine hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)